Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate
Purpose
The purpose of the study is to assess the effectiveness of the HALT COVID Ambassador educational outreach program on increasing likelihood to vaccinate against COVID-19
Conditions
- Covid19
- Vaccine Refusal
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Unlikely to vaccinate in next month - Age >=18 years - Self-identification as Black or African American - Ability to understand and speak English - Willingness to engage with HALT COVID Ambassador via in-person or virtual sessions exploring questions and concerns about vaccines
Exclusion Criteria
- Unable or unwilling to give informed consent
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Intervention |
|
|
No Intervention Usual care |
|
Recruiting Locations
More Details
- NCT ID
- NCT04930965
- Status
- Completed
- Sponsor
- Tulane University
Detailed Description
Investigators will use a randomized controlled trial to test the effectiveness of HALT COVID educational outreach by HALT COVID Ambassadors. HALT COVID Ambassadors will receive training to answer common vaccine questions & address misconceptions; conduct motivational interviewing; and implement basic behavioral economics and related strategies to remove barriers to vaccination. A random sample of FQHC patients will be identified in EHR data downloads of adult patients seen in the last year and contacted by telephone to gain consent and assess eligibility. A total of 100 individuals will be enrolled into the trial and randomized to intervention (engagement with the HALT COVID Ambassador over a 1 month period via in-person or virtual sessions exploring their own questions and concerns about vaccines) or usual care (no extra engagement). Baseline, 1-month, and 2-month follow-up surveys will assess for vaccine likelihood.